ReviewBME frontiers2025
Biomaterials for Modulating the Immune Microenvironment in Rheumatoid Arthritis.
Review in BME frontiers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- CCL17-neutralizing and esterase-responsive core-shell microgels for endogenous Tregs recruitment and functional enhancement in myocardial infarction.Bioactive materials · 2026Article
- Heme cascade-triggered nanovesicles for myocardial ischemic core delivery.Bioactive materials · 2026Article
- Next-Generation Joint-on-a-Chip: Toward Precision Mechanical Control in Multi-Tissue Systems.Nano-micro letters · 2026Review
- Nrf2 as a redox checkpoint in autoimmune joint inflammation: microenvironmental redox control across the arthritis spectrum.Frontiers in immunology · 2026Review
- Molecular pathways and immune microenvironment regulation in stem cell therapy for thin endometrium: a comprehensive narrative review.Frontiers in immunology · 2026Review
- Protease activated receptor inhibitors in rheumatoid arthritis: a new frontier in treatment.Inflammopharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease characterized by joint swelling and bone destruction. Despite an incomplete understanding of its genesis, RA is tightly linked to the intricate immunological milieu, involving disruptions in molecular signaling and an imbalance between the innate and adaptive immune systems. With advancements in biomaterials science, the role of biomaterials in RA treatment has evolved from mere drug delivery systems to therapeutic microenvironment modulators, providing drug-independent treatment strategies for RA. In this review, we will delve into the immune microenvironment of RA, focusing on contributions of adaptive immunity, innate immunity, damage-associated molecular patterns (DAMPs), cytokines, and signaling pathways to disease's pathogenesis and inflammation. We provide a detailed analysis of the applications of novel nonpharmaceutical biomaterials in RA treatment, categorized into 3 key mechanisms: biofactor and signaling pathway regulation, endogenous gas adjustment, and immune cell modulation. The composition, form, therapeutic principles, and treatment efficacy of these biomaterials will be explored. The thorough discussion of these topics will offer a fresh viewpoint on RA treatment strategies and guide future research directions.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.